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Improved protein-based vaccines should facilitate the goal of
effective vaccines against HIV and other pathogens. With respect
to T cells, the efﬁciency of immunization, or “immunogenicity,” is
improved by targeting vaccine proteins to maturing dendritic cells
(DCs) within mAbs to DC receptors. Here, we compared the capac-
ity of Langerin/CD207, DEC205/CD205, and Clec9A receptors, each
expressed on the CD8+ DC subset in mice, to bring about immuni-
zation of microbial-speciﬁc T cells from the polyclonal repertoire,
using HIV gag-p24 protein as an antigen. α-Langerin mAb targeted
splenic CD8+ DCs selectively in vivo, whereas α-DEC205 and
α-Clec9A mAbs targeted additional cell types. When the mAb
heavy chains were engineered to express gag-p24, the α-Langerin,
α-DEC205, and α-Clec9A fusion mAbs given along with a matura-
tion stimulus induced comparable levels of gag-speciﬁc T helper 1
(Th1) and CD8+ T cells in BALB/c × C57BL/6 F1 mice. These immune
T cells were more numerous than targeting the CD8− DC subset
with α-DCIR2-gag-p24. In an in vivo assay in which gag-primed T
cells were used to report the early stages of T-cell responses,
α-Langerin, α-DEC205, and α-Clec9A also mediated cross-presenta-
tion to primed CD8+ T cells if, in parallel to antigen uptake, the DCs
were stimulated with α-CD40. α-Langerin, α-DEC205, and α-Clec9A
targeting greatly enhanced T-cell immunization relative to non-
binding control mAb or nontargeted HIV gag-p24 protein. There-
fore, when the appropriate subset of DCs is targeted with
a vaccine protein, several different receptors expressed by that
subset are able to initiate combined Th1 and CD8+ immunity.
antigen presentation | C-type lectins | cross-priming
A major goal in the development of effective vaccines againstpathogens such as HIV and malaria is the induction of
durable and protective T-cell immunity. Attenuated viral vectors
are being emphasized widely as a vaccine platform to elicit T-cell
immunity in humans (1). Attenuated vectors have potential lim-
itations with respect to immunogenicity and repeated use, how-
ever (2). Protein vaccines could provide a stand-alone or com-
plementary platform (e.g., to viral vectors), with relative ease of
production and ability to be repeatedly injected. Proteins are
poorly immunogenic for T cells, however, even when adminis-
tered repeatedly in high doses.
Recent progress in immunobiology provides the potential to
overcome this obstacle. The immunogenicity of proteins can be
greatly enhanced by improving the delivery of protein to dendritic
cells (DCs). To do this, one approach is to introduce the protein
into mAbs that efﬁciently and speciﬁcally target to DC receptors
in situ, within lymphoid tissues, and then to coadminister the
fusion antibody with an appropriate agonist for DC maturation
[reviewed in (3, 4)]. Delivery of vaccine proteins within mAbs
increases the efﬁciency of antigen presentation on MHC class I
and II molecules ∼100-fold and allows protein vaccines to induce
T helper 1 (Th1) type CD4+ T cells and CD8+ T cells (5–8).
The DC system is composed of different subsets with distinct
cell surface markers and biological functions (9–11). Three of the
major DC subsets in mouse secondary lymphoid organs are as
follows: (i) CD11chighCD8− DCs, (ii) CD11chighCD8+ DCs, and
(iii) CD11cintCD45RA+ Gr1+ plasmacytoid DCs (PDCs) (12).
For example, when CD8− DCs take up antigen, they more efﬁ-
ciently form MHC II complexes (13) and elicit T cells producing
IFN-γ and IL-4 (14, 15). By contrast, CD8+ DCs are the major
producer of IL-12 on activation (16, 17) and promote Th1
responses. These DCs also are specialized to capture dying cells
(18, 19) and to cross-present antigens on MHC class I (20–24).
The ability of CD8+ DCs to initiate combined Th1 and cytotoxic
responses in vivo has made them a most logical target for vaccine
development, including protein vaccines.
To date, the uptake receptors expressed by CD8+ DCs include
several molecules with external C-type lectin domains (25), such
as DEC205/CD205, Langerin/CD207, and Clec9A (26–30). There
is little information comparing the immunogenicity of proteins
targeted to the same subset of DCs using different α-receptor
mAbs, however. Previously, we have compared the presenta-
tion of ovalbumin (OVA) to T-cell receptor (TCR) transgenic T
cells using α-DEC205 and α-Langerin mAbs for CD8+ DCs and
α-DCIR2 mAb for CD8− DCs (31). Here, we have assessed the
capacity of different receptors on the CD8+ DC subset to bring
about the priming of scarce microbial-speciﬁc T cells in the poly-
clonal repertoire, using the HIV protein gag-p24 as an antigen,
and compared these lectins with gag targeted to the DCIR2 lectin
on splenic CD8−DCs.We show that α-Langerin targets the CD8+
DC subset selectively but that α-Langerin, α-DEC205, and
α-Clec9AmAb are each effective in inducing gag-speciﬁc Th1 and
CD8+ T-cell responses. α-DCIR2 targeting was less effective at
priming such responses from a polyclonal T-cell repertoire, how-
ever. Our ﬁndings indicate that uptake of proteins through dif-
ferent receptors on CD8+ DCs has similar potential for inducing
or priming Th1 and CD8+ immunity.
Results
α-Langerin Selectively Targets CD8+ DCs in Spleen, Whereas α-DEC205
and α-Clec9A Label CD8+ DCs and Some Other Leukocytes. To assess
speciﬁc targeting of α-receptor mAbs to DCs in vivo, 10 or 5 μg of
Alexa 647-labeled α-Langerin, α-DEC205, α-Clec9A, α-DCIR2, or
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control mAb was injected i.p. into C57BL/6 or C×B6 F1mice. The
percentage of splenic DCs containing Alexa 647 3 h after admin-
istration was subsequently examined by FACS (Fig. 1, using the
gating strategy in Fig. S1). In both strains of mice, the injected
α-DEC205 mAb labeled most of the CD8+ DCs, but no labeling
was observed in DEC205 B6 KO mice. In addition to CD8+ DCs,
α-DEC205 bound to other leukocyte populations (Fig. S2), which
corresponds to the observed expression of DEC205 in these cells
(32), although the labeling of CD8+ DCs (mean ﬂuorescence in-
tensity) was threefold higher on CD8+ DCs relative to granulo-
cytes and greater than threefold relative to other types of leuko-
cytes (Fig. 1 and Fig. S2). α-Clec9A targeted to CD8+ DCs and
PDCs but not to other leukocytes (Fig. 1 and Fig. S2). In contrast
to α-DEC205 or α-Clec9A, α-Langerin targeted only to CD8+
DCs in the spleens of C×B6 F1 mice (Fig. 1A) and not to PDCs or
other cells, including B cells, T cells, natural killer (NK) cells,
monocytes, macrophages, and granulocytes (Fig. S2 A and B),
consistent with prior data that Langerin is a speciﬁc marker for
CD8+DCs (27).Only 25%ofCD8+DCs in B6micewere targeted
with α-Langerin mAb (Fig. 1B), however, which is consistent with
data showing that Langerin is only expressed at low levels in CD8+
DCs in B6 mice (33, 34). Labeling of CD8+ DCs was abrogated in
Langerin B6 KOmice. In both B6 and C×B6 F1 strains, α-DCIR2
selectively stained CD8− DCs and nontargeted control mAb did
not label any leukocyte (Fig. 1 and Fig. S2). These results indicate
that i.p. injection of α-Langerin mAbs targets CD8+ DCs selec-
tively in vivo, and in C×B6 F1 mice, it labels this subset to a mag-
nitude comparable to that of α-DEC205 mAbs and α-Clec9A.
α-Langerin-, α-DEC205-, and α-Clec9A-gag-p24 Inoculated in the
Presence of α-CD40 and Induces Comparable Th1 and CD8+ T-Cell
Responses in C×B6 F1 Mice. To examine the capacity of different
receptors to immunize scarce microbial-speciﬁc T cells in the
polyclonal repertoire, as contrasted with a prior study on presen-
tation to OVA-speciﬁc TCR transgenic T cells using α-Langerin,
α-DEC205, and α-DCIR2 (31), we genetically engineered mAbs
against Langerin (L31) (33), DCIR2 (33D1) (35), DEC205
(NLDC145) (36, 37), and a nonreactive control Ig (GL117) (38) to
express HIV gag-p24. We also cloned and engineered an antibody
against the more recently described receptor Clec9A to express
HIV gag-p24 (10B4) (28). In each case, the fusion H chain had
a molecular mass of ∼75 kDa (Fig. S3A, Left), as opposed to ∼50
kDa for unmodiﬁed mouse IgG1, and it also reacted with α-mouse
Ig and α-p24 mAbs by Western blotting (Fig. S3A, Right). In con-
trast to control Ig-gag-p24, these fusion mAbs bound to CHO cells
expressing the respective receptor (Fig. S3B, red histograms) but
not to untransfected CHO (Fig. S3B, blue histograms, CHO neo).
Thus, each mAb to four endocytic receptors can be successfully
engineered to express HIV gag-p24 as an antigen.
To compare T-cell responses induced by HIV gag-p24 tar-
geted within different α-receptor antibodies, we immunized
C×B6 F1 mice with 5 μg of α-Langerin-, α-DEC205-, α-Clec9A-,
α-DCIR2-, and control Ig-gag-p24 mAbs along with 25 μg of
α-CD40 mAb and 50 μg of polyriboinosinic:polyribocytidylic acid
(poly IC) as a maturation stimulus. C×B6 F1 mice were chosen
for this experiment for several reasons. First, broad CD4+ T-cell
responses directed to at least three different deﬁned CD4+ T-cell
peptide mimetopes are achieved by combining H-2d and H-2b
haplotypes in F1 mice (6). Second, the CD8+ T-cell response is
directed to a deﬁned gag 197–205 peptide presented only on H-2d
(39) but not on H-2b. Finally, only in C×B6 F1 but not in C57BL/
6 mice were all CD8+ DCs similarly targeted with α-Langerin,
α-DEC205, and α-Clec9A mAbs (Fig. 1).
Two weeks after immunization, antigen-speciﬁc responses were
evaluated by IFN-γ production in response to HIV gag-p24 pep-
tides by multicolor ﬂow cytometry. α-Langerin-, α-DEC205-, and
α-Clec9A-gag-p24 induced signiﬁcantly stronger gag-speciﬁc, IFN-
γ–producing, CD4+ T-cell responses compared with α-DCIR2-
gag-p24 (Fig. 2A andB; P< 0.01, data not shown) with frequencies
of>0.5%of IFN-γ–producing CD3+CD4+T cells after a single i.p.
injection. No CD4+ T-cell immunity was observed following a sin-
gle immunization with control Ig-gag-p24 and when fusion anti-
bodiesweregiven in theabsenceof anadjuvant, as shownpreviously
(6). When we performed similar experiments in C57BL/6 mice,
α-DEC205-gag-p24 led to higher CD4+ T-cell responses than
α-Langerin-gag-p24 (Fig. S4 A and B), possibly because Langerin
was less expressed on CD8+ DCs in C57BL/6 mice (33, 34). Fewer
respondingCD4+T cells were seenwith one dose ofα-DCIR2-gag-
p24 or nontargeted HIV gag-p24 protein given along with α-CD40
and poly IC.
When we measured CD8+ T-cell responses in C×B6 F1 mice
by intracellular cytokine staining, we found that a single vaccina-
tion of α-Langerin-, α-DEC205-, and α-Clec9A-gag-p24 mAb plus
α-CD40/poly IC induced comparable signiﬁcant numbers of IFN-
γ–producing CD8+ T cells, whereas α-DCIR2-gag-p24 did not
cross-prime (Fig. 2C; P< 0.01, data not shown). An enzyme-linked
immunospot (ELISPOT) assay revealed that the CD8+ T-cell re-
sponse was directed to a peptide in p24 pool 2, which contained
a previously deﬁned gag 197–205 peptide sequence presented on
H-2Kd (39) (Fig. 2D).We conclude that a single immunization of
HIV gag-p24 targeted within 5 μg of α-Langerin, α-DEC205, and
α-Clec9A fusionmAb induced comparable Th1 and CD8+ T-cell
responses, which were greater relative to DCIR2 targeting.
HIV gag-p24 Targeted in α-Langerin, α-DEC205, and α-Clec9A mAbs
Requires an Adjuvant for in Vivo Cross-Presentation to Primed gag-
Speciﬁc CD8+ T Cells. To assess the early proliferative response to
HIV gag protein following targeting to Langerin, DEC205, and
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Fig. 1. α-Langerin, α-DEC205, and α-Clec9A are captured
by CD8+ DCs in vivo, whereas α-DCIR2 is taken up by CD8−
DCs. C×B6 F1mice (A) or C57BL/6mice (B) were inoculated
i.p. with 5 or 10 μg of each Alexa 647-labeled α-Langerin,
α-DEC205, α-Clec9A, and α-DCIR2 mAb. GL117 mAb la-
beled with Alexa 647 (blue histograms) was used as
a control mAb. Data are plotted with the higher dose of
GL117 because we did not see differences between in-
oculation of 5 or 10 μg. When available, we also added
KO mice in the C57BL/6 background as an additional
control (DEC205 KO and Langerin KO mice, gray histo-
grams). Uptake of labeled mAb by splenocytes was eval-
uated 3 h after inoculation by multicolor ﬂow cytometry
(Fig. S1) in CD11chighCD8α+ DCs (Fig. S1, population C),
CD8α− DCs (Fig. S1, population B), and PDCA-1+ PDCs (Fig.
S1, population D). One experiment representative of two
to three with similar results is shown.
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Clec9A in vivo, we used polyclonal memory T cells from C×B6
F1 mice that had been immunized twice with adenovirus expres-
sing HIV gag (Fig. 3A). As shown previously (6), adenovirus-gag
induced high frequencies of gag-speciﬁc CD8+ T cells (∼5%)
but low frequencies of gag-speciﬁc CD4+ T cells (∼0.3%). In ini-
tial experiments, gag-speciﬁc splenic T cells were enriched from
C×B6 F1 Thy 1.2+ mice, labeled with carboxylﬂuorescein suc-
cinimidlylester (CFSE), and adoptively transferred into C×B6 F1
Thy 1.1+ recipients (Fig. 3A). One day later, the mice were in-
jected with either PBS, α-DEC205-gag-p24 mAb alone, α-CD40
alone, or a combination of α-DEC205-gag-p24 mAb plus α-CD40
(Fig. 3 A and B), where prior data had shown that α-CD40 allows
DC-targeted antigens to elicit immunity (38). Cross-presentation
was evaluated in the spleen 4 d later by T-cell proliferation and
IFN-γ production of gag p24-speciﬁc CD8+ T cells in a CFSE
dilution and intracellular cytokine assay (Fig. 3 A and B). The
gag-speciﬁc CD8+ T cells proliferated and produced IFN-γ on
restimulation with gag-p24 peptide mix only when mice were co-
inoculated with α-DEC-gag-p24 plus α-CD40, whereas no pro-
liferative or IFN-γ responses were induced to either α-DEC-gag-
p24 alone, α-CD40 alone, or medium. Thus, DEC205 mediated
efﬁcient cross-presentation of HIV gag-p24 in vivo but only when
α-CD40 was given along with the fusion mAb. We also tested
CD40−/−mice to show that CD40 expression on recipient but not
A
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Fig. 2. α-Langerin, α-DEC205, and α-Clec9A induce com-
parable Th1 and CD8+ T-cell responses in C×B6 F1 mice. (A)
C×B6 F1 mice were immunized with 5 μg of α-receptor
fusion mAbs in the presence of 50 μg of poly IC and 25 μg
of α-CD40 [adjuvant (Adj)]. Fourteen days later, spleno-
cytes were restimulated in vitro with HIV gag-p24 or HIV
gag-p17 (negative control) peptide mix in the presence of
Brefeldin A for 6 h. Intracellular staining was performed to
detect IFN-γ in CD3+CD4+ T cells. (B) As in A, but % of IFN-γ+
CD4+ T cells is shown as mean ± SD of four to six experi-
ments with two to three mice per group. (C) As in A, but
this time, the % of IFN-γ+ CD8+ T cells is shown as mean ±
SD of four to six experiments with two to three mice per
group. (D) As in A, but after 14 d, puriﬁed splenic CD8+ T
cells were restimulated with CD11c+ bead-puriﬁed DCs and
CD8 nanomer (gag-p24 197-205), p24 reactive pool 2, or
p17 nonreactive peptide mix. IFN-γ production was evalu-
ated by ELISPOT. Data are representative of three to four
similar experiments with three mice pooled in each ex-
periment. n.d., not determined.
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Fig. 3. α-Langerin-, α-DEC205-, and α-Clec9A–targeted HIV
gag-p24 requires α-CD40 for in vivo cross-presentation by
DCs to primed gag-speciﬁc CD8+ T cells. (A) Schematic for the
design of the adoptive transfer experiment (Materials and
Methods). (B) Thy 1.1 mice transferred 1 d before with CFSE-
labeled Thy 1.2+ adenovirus-primed T cells were challenged
with 25 μg of α-CD40 alone, 5 μg of α-DEC-gag-p24 alone,
medium, or a combination of 5 μg of α-DEC-gag-p24 and 25
μg of α-CD40. Four days after challenge, IFN-γ production
and proliferation of transferred Thy 1.2+ CD3+CD8+ T cells
were assessed in a 6-h in vitro restimulation assay. (C) As in B,
but adoptively transferred, gag-primed, enriched T cells were
challenged with 25 μg of α-CD40 in combination with 5 μg of
α-DEC205-, α-Langerin-, α-DCIR2-, α-Clec9A-, or control Ig-
gag-p24 mAbs. In all cases, one experiment of two with
similar results is shown.
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donor cells was essential for DEC-mediated cross-presentation
of HIV gag in vivo (Fig. S5A). In addition, α-DEC-gag-p24 plus
α-CD40 induced responses by adenovirus-gag–primed CD8+ T
cells but not by adenovirus-OVA–speciﬁc CD8+ T cells, indica-
ting that proliferation and IFN-γ production were gag-speciﬁc
(Fig. S5B). These in vivo ﬁndings complement prior studies
showing that targeting to DEC205 enhanced cross-presentation
of HIV gag to antigen-primed human and mouse CD8+ T cells in
vitro (7, 8).
With these results, we proceeded to compare the capacity
of several DC uptake receptors to mediate cross-presentation of
HIV gag in vivo. Speciﬁcally, C×B6 F1 Thy 1.1+ mice were injec-
ted with 5 μg of α-Langerin-, α-DEC205-, α-Clec9A-, α-DCIR2-,
and control Ig-gag-p24 fusion mAb along with α-CD40 1 d after
inoculating CFSE-labeled gag-speciﬁc enriched T cells. When we
analyzed the proliferation and IFN-γ secretion by gag-primed
CD8+ T cells 4 d later in splenocytes restimulated for 6 h in the
presence or absence of reactive gag-peptide mix, we found that
α-Langerin-, α-DEC205-, and α-Clec9A-gag-p24 induced pro-
liferation and IFN-γ production by gag-speciﬁc CD8+ T cells but
that α-DCIR2- or control Ig-gag-p24 did not (Fig. 3C). In contrast,
all antireceptor mAbs, including α-DCIR2-gag p24, were able to
expand adenovirus-gag–primed gag-speciﬁc CD4+ T cells (Fig.
S5C). Similar results were found when 1 vs. 5 μg of receptor mAbs
was given along with α-CD40. We conclude from these experi-
ments that α-Langerin, α-DEC205, and α-Clec9A mAbs are com-
parable in their capacity tomediate cross-presentation of HIV gag
in vivo byDCs and that cross-presentation of antigen to polyclonal
primed T cells only occurs if the DCs undergo maturation in par-
allel to antigen uptake.
Enhanced gag-Speciﬁc CD4+ T-Cell Immunity Following Prime/Boost
Immunization Using Poly IC or Poly ICLC as the Only Adjuvant. To test
the efﬁcacy of α-receptor antibodies to induce antigen-speciﬁc
CD4+ T cells in a prime-boost regimen, we injected C57BL/6
mice twice i.p. over a 4-wk period with 5 μg of α-Langerin-,
α-DEC205-, α-Clec9A-, α-DCIR2, or control Ig-gag-p24 (which
contain ∼1.5 μg of gag-p24 protein) or with 5 μg of nontargeted
HIV gag-p24 protein along with 50 μg of poly IC or poly ICLC as
an adjuvant. The latter is poly IC formulated together with poly
L-lysine and carboxymethylcellulose. Poly IC and poly ICLC are
synthetic dsRNAs that are proving to be superior adjuvants for
T-cell immune responses (40, 41). Because both poly IC and poly
ICLC were comparable in the response induced after prime-
boost, they were used interchangeably. Previously, we reported
that two immunizations with α-DEC205-gag-p24 and 50 μg of
poly IC induced higher frequencies of cytokine-producing CD4+
T cells than a single immunization of α-DEC205-gag-p24 plus
50 μg of poly IC or two doses of α-DEC205-gag-p24 plus 10 μg of
poly IC (42). Two weeks after the boost, the frequency of gag
p24-speciﬁc CD4+ T cells producing IFN-γ, IL-2, or TNF-α was
greatest with two doses of α-Langerin, α-DEC205, and α-Clec9A
and poly IC or poly ICLC (Fig. 4 A and B and Fig. S6 A and B).
In contrast, fewer IFN-γ–producing CD4+ T cells were seen with
two doses of α-DCIR2- or control Ig-gag-p24 or with soluble
HIV gag-p24 protein plus poly IC or poly ICLC. We did not
ﬁnd signiﬁcant differences between α-Langerin-, α-DEC205-, and
α-Clec9A-gag-p24; however, targeting any of these lectins showed
signiﬁcant differences from either control Ig-, α-DCIR2-, or
nontargeted gag-p24 protein (P< 0.01, data not shown).When we
tested a lower concentration of protein vaccine (i.e., 0.5 μg of fu-
sion mAb or nontargeted p24 protein given with poly IC or poly
ICLC), we identiﬁed IFN-γ–producing CD4+ T cells only in mice
immunized with two doses of α-DEC205-gag-p24 mAb and poly
IC or poly ICLC (Fig. S6C). We conclude that targeting vaccine
proteins with 5 μg of α-Langerin, α-DEC205, or α-Clec9A mAb is
more effective at initiating IFN-γ–producing CD4+ T-cell immu-
nity than using nontargeted gag-p24 protein or α-DCIR2- and
control Ig-gag-p24.
Discussion
The development of protein-based vaccines will beneﬁt from
identifying principles that lead to cross-presentation of antigens on
MHC Imolecules and cross-priming of CD8+T cells. Prior studies
primarily examining the responses of OVA-speciﬁc T cells in
C57BL/6 mice, often with TCR transgenic T cells as reporters,
have shown that theCD8+ subset ofDCs is particularly effective at
cross-presentation. In this study, we addressed the logical need to
compare different surface receptors on CD8+ DCs for their ca-
pacity to improve antigen uptake and presentation in vivo, par-
ticularly cross-presentation and cross-priming.
OVA has been a valuable tool for research because of its high
sensitivity [e.g., responses are observed with just 1 pM SIIN-
FEKL peptide in vitro (43)]. Here, we focused on the more
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Fig. 4. Enhanced gag-speciﬁc immunity by prime/boost im-
munization. (A) C57BL/6 mice were primed and boosted 4 wk
apart with 5 μg of α-receptor mAbs or nontargeted gag-p24
protein in the presence of 50 μg of poly IC or poly ICLC as an
adjuvant (Adj). IFN-γ production was evaluated by intra-
cellular cytokine staining 2 wk after boost in the CD3+CD4+
gated cells in response to reactive HIV gag-p24 or nonreactive
HIV gag-p17 peptide mix. (B) As in A, but mean ± SD from
three to ﬁve experiments with three to four mice per group
are shown.
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representative protein, HIV gag-p24, where it is known that
targeting to DEC205+ DCs leads to strong Th1 immunity in mice
(8, 42). HIV gag is likely to be an important antigen for eliciting
T-cell immunity with an HIV vaccine [e.g., when this protein is
the only HIV antigen in a vaccine, signiﬁcant protection is in-
duced in the simian immunodeﬁciency virus rhesus macaque
model of disease (44)]. Using HIV gag-p24 targeted within mAbs
to different C-type lectins on CD8+ DCs, we found that targeting
of any one of three receptors—Langerin/CD207, DEC205/
CD205, and Clec9A/DNGR1—led to similar levels of priming of
CD4+ and CD8+ T cells. Targeting of DCIR2 on another CD8−
DC subset failed to cross-prime and induced weaker CD4+ IFN-
γ–secreting T-cell responses. Consistent with previous reports (5,
29, 42), we used an adjuvant, α-CD40 plus poly IC, to elicit T-cell
immunity with these α-receptor mAbs. Our ﬁndings are at this
time limited to the protocol we used in a large number of animals
and experiments [i.e., we used one dose (5 μg) of fusion mAb and
one type of adjuvant, and we evaluated the acute response to
priming and boosting by cytokine-producing T cells]. Further
research is needed to assess the capacity of different DC uptake
receptors to induce memory T-cell responses as well as acute and
memory B-cell responses. Nonetheless, our results indicate that
several receptors allow CD8+ DCs to exert their capacity to
bring about combined CD8+ and CD4+ T-cell immunity.
When we used sensitive FACS analyses to compare the tar-
geting of each of the mAbs to the major types of leukocytes in
spleen, we found that α-DEC205 was picked up in large amounts
by CD8+ DCs but also in lower amounts by T cells, granulocytes,
NK cells, and B cells. For α-Clec9A, uptake was observed in both
CD8+ DCs and PDCs. Only α-Langerin was fully selective for
targeting CD8+ DCs in spleen. These mAb targeting results
replicate prior data on the expression of these lectins by DCs
(27–29, 32, 34). DEC205 and Langerin are also expressed by skin
dermal DCs and Langerhans cells (45). Because immunization of
CD8+ T cells was similar when gag-p24 was delivered in three
mAbs to distinct lectins on the CD8+ DC subset, our ﬁndings
imply that the subset of DCs and not the receptor-capturing
antigen is a dominant force in bringing about the measured T-
cell priming following antigen uptake and that the CD8+ subset
and not other DCs or other leukocytes that were targeted by
α-DEC205 acts as the dominant cell for cross-priming in vivo
when α-CD40 or poly ICLC is used as an adjuvant.
We also noted that the targeting of each lectin on CD8+ DCs
led to Th1 type CD4+ T-cell immunity, whereas targeting via
DCIR2 on CD8− DCs was less efﬁcient at inducing IFN-γ. At
this time, it is not feasible to target other lectins selectively on
CD8− DCs. Nevertheless, our data lead to the conclusion that
the induction of combined Th1 and CD8+ T-cell immunity to
a protein is primarily determined by the subset of DCs rather
than the particular receptor for antigen uptake, with additional
input from the adjuvant used.
Materials and Methods
Mice. We purchased C57BL/6J (B6) and BALB/CJ mice from the The Jackson
Laboratory and BALB/c × C57BL/6 (C×B6) F1 Thy 1.2+ mice from Harlan.
CD40−/− BALB/c mice were from The Jackson Laboratory. C×B6 F1 Thy 1.1+
mice were obtained by breeding B6 Thy 1.1+ male mice (The Jackson Labo-
ratory) with BALB/c Thy 1.1+ female mice. DEC205 KO mice were obtained
from M. Nussenzweig (The Rockefeller University, New York). Langerin
diphtheria toxin receptor (DTR) was kindly provided by one of the authors
(B.E.C.), and mice were bred in-house as homozygotes [Langerin DTR+/+ mice
do not express Langerin, becoming Langerin KO mice (46)]. Mice were
maintained under speciﬁc pathogen-free conditions and used at 6–8 wk of
age in accordance with The Rockefeller University Animal Care and Use
Committee guidelines.
Reagents. All ﬂuorochrome-labeled antibodies are listed in Table S1. mAbs to
Langerin (L31) (33), DCIR2 (33D1) (35), DEC205 (NLDC145) (36, 37), Clec9A
(10B4) (28), control Ig (GL117) (38), and CD40 (IC10) were produced from
hybridoma supernatants; puriﬁed on protein G (Pierce); and, when neces-
sary, labeled with Alexa 647 (Invitrogen) per the manufacturer’s instructions.
Anti-CD11c beads (N418), anti-CD8 beads (Ly-2), and anti-CD19 beads were
from Miltenyi Biotec. Other reagents were Live/Dead Fixable Aqua or Violet
vitality dye (Invitrogen) and DAPI (Sigma).
Peptides. Overlapping (staggered by four amino acids) 15-mer peptides
spanning the entire HIV gag-p17 or -p24 sequence were synthesized by
H. Zebroski in the Proteomics Resource Center of The Rockefeller University.
HIV gag-p17 or -p24 peptides were resuspended at 3 mg/mL per peptide in
DMSO and added to immune assays at a rate of 1 μg/mL.
Fusion HIV gag-p24 mAbs. DNA for HIV gag-p24 (aa 133–363 derived from HIV
isolate BH10) was cloned in frame into the COOH terminus of the heavy
chains of α-mouse-DEC205, -Langerin, -DCIR2, -Clec9A, and -control Ig, as
previously described (6). Fusion mAbs against DEC205, Langerin, DCIR2, and
control IgG were expressed by transient transfection (calcium phosphate) in
293T cells in serum-free DMEM supplemented with Nutridoma SP (Roche
Applied Science). Fusion mAbs for α-Clec9A-gag-p24 were produced by
transient transfection in Freestyle 293F cells (Invitrogen) using the Freestyle
293 Expression System (Invitrogen). The mAbs were puriﬁed on protein G
columns (GE Healthcare Bio-Sciences Corp.) and characterized by SDS/PAGE
and Western blotting using α-mouse IgG1-HRP (Southern Biotech) or HRP-
α-gag-p24 (ImmunoDiagnostics). mAb binding was veriﬁed on CHO cells
stably transfected with the respective receptor by FACS using phycoerythrin-
conjugated goat α-mouse IgG (Jackson ImmunoResearch).
Soluble gag-p24 Protein. Soluble FLAG gag-p24 protein (8) was expressed by
CHO cells and puriﬁed from culture supernatant using anti-FLAG M1 Afﬁnity
Gel (Sigma–Aldrich) following the manufacturer’s instructions.
Targeting of Alexa 647-Labeled mAbs. C57BL/6 or C×B6 F1 mice were injected
i.p. with 10 or 5 μg of α-receptor or control mAbs labeled with Alexa 647
for 3 h.
Immunizations.Mice were injected i.p. once with fusion mAbs or HIV gag-p24
protein with a stimulus for DC maturation, which was 50 μg of poly IC
(InVivoGen) together with 25 μg of IC10 agonistic α-CD40 mAb (47). In other
experiments, we used a prime boost regimen in which α-CD40 was omitted
and 50 μg of poly IC (Thermo Scientiﬁc) or poly ICLC (Oncovir, Inc.) was the
adjuvant for both prime and boost, which were given 1 mo apart. To assess
cross-presentation of HIV gag-p24 in vivo, mice were immunized twice i.m.
with 107 pfu of adenovirus expressing HIV gag-p24 or OVA.
Intracellular Cytokine Staining. Bulk splenocytes were either restimulatedwith
the entire reactive HIV gag-p24 or nonreactive HIV gag-p17 15-mer peptide
mix (peptides at 1 μg/mL) in the presence of 2 μg/mL costimulatory α-CD28
(clone 37.51; American Type Culture Collection) for 6 h at 37 °C, adding
Brefeldin A (10 μg/mL; Sigma–Aldrich) for the last 5 h to allow accumulation
of intracellular cytokines. Cells were washed, incubated for 10 min at 4 °C
with 2.4G2 mAb to block Fcγ receptors, and stained with mAbs against
surface molecules for 20 min at 4 °C. Cells were then ﬁxed, permeabilized
(BD Pharmingen), and stained with mAbs against cytokines. A total of 1–3 ×
105 live-CD3+ cells were acquired on a Becton Dickinson (BD) LSR II ﬂow
cytometer, and data were analyzed with FlowJo Software (Tree Star, Inc.).
ELISPOT. ELISPOT Multiscreen-HA MAHA 54510 (Millipore) plates were coated
with 10 μg of puriﬁed α-mouse IFN-γ mAb (clone R4-6A2; BD Biosciences)
overnight at 4 °C and subsequently blocked by incubation with 1% PBS-BSA
for at least 1 h at 37 °C. A total of 3 × 105 bead-puriﬁed CD8+ T cells were
cultured for 2 d with 1 × 105 CD11c+ spleen DCs in the presence of 1 μg/mL
previously deﬁned H-2Kd restricted gag peptide (AMQMLKETI, p24 197–205),
a 15-mer peptide mix containing the gag-p24 197–205 epitope (gag-p24 re-
active pool 2), or gag-p17 nonreactive peptide mix. Plates were developed
with α-IFN-γ biotinylated mAb (BD Biosciences), and spots were visualized
with avidin-HRP (Vector Laboratories), followed by diaminobenzidine as
a substrate (Invitrogen). Spots were counted in an ELISPOT reader (Auto-
immun Diagnostika GmBH).
Leukocyte Preparation. Spleens were harvested and digested for 25 min at
37 °C in Hanks’ buffer (Gibco) containing 400 units/mL Collagenase D (Roche)
and 50 μg/mL DNaseI (Roche). A total of 5 mM EDTA (Gibco) was added for
the last 5 min. For analysis of different leukocytes in the spleen, cells were
selected with α-CD19 magnetic beads (Miltenyi Biotec), and for enrichment
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of DCs, splenocytes were incubated with α-CD11c beads (Miltenyi Biotec)
following manufacturer’s instructions.
Rapid Assay to Evaluate Cross-Presentation of HIV gag-p24 in Vivo. To evaluate
cross-presentation of HIV gag-p24 by DCs in vivo, antigen-primed T cells
isolated from mice that had been primed and boosted 4 wk apart with
adenovirus-gag or adenovirus-OVA were enriched from spleen cell suspen-
sions by excluding MHC class II+ cells, macrophages, and B cells using
a combination of α-MHCII (TIB120), α-B220, and α-F4/80 rat mAb and α-rat
IgG Dynabeads (Invitrogen). T cells were subsequently labeled at 107 cells/mL
with 5 μM CFSE (Invitrogen/Molecular Probes) for 10 min at 37 °C and
adoptively transferred into Thy 1.1+ recipient mice (one spleen equivalent
was transferred per mouse). One day later, targeting mAbs were injected i.p.
in the presence or absence of a maturation stimulus, which was 25 μg of
agonistic α-CD40 IC10 mAb. Four days later, the transferred T cells were
evaluated for proliferation by CFSE dilution and IFN-γ production after
surface staining for Thy 1.2 (transferred T cells), CD3, CD4, and CD8 and
intracellular cytokine staining for IFN-γ as described above.
Statistical Analysis. Data reported in the ﬁgures represent the average of at
least three independent experiments. Error bars represent the SD. Data were
analyzed and charts were generated using Prism 5 (GraphPad Software).
Statistical signiﬁcance was determined by an unpaired t test.
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